Piper Sandler downgraded Karuna Therapeutics (KRTX) to Neutral from Overweight with a price target of $330, up from $268, after the company agreed to be acquired by Bristol Myers (BMY) for $330 per share.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KRTX:
- M & A News: Bristol-Myers (NYSE:BMY) to Acquire Karuna for $14B
- Karuna Therapeutics’ KarXT results in schizophrenia published in The Lancet
- Karuna Therapeutics initiated with bullish view at Citi, here’s why
- Karuna Therapeutics initiated with bullish view at Deutsche Bank, here’s why
- After AbbVie agrees to buy Cerevel, analysts weigh in on who may be next
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue